Tango Therapeutics (TNGX) is back in focus after reporting a first quarter net loss of US$45.51m, updating investors on clinical progress, and confirming multiple board resignations and leadership changes.

Despite the sharp 17.33% one day and 18.83% one month share price declines following the wider first quarter loss and board exits, Tango Therapeutics still carries strong momentum, with a 130.24% year to date share price return and a very large 1 year total shareholder return.

If you are looking beyond a single oncology stock, this could be a good moment to see what else is moving and check out 32 healthcare AI stocks.

With the stock down over the past month but still showing very strong gains over the past year, and trading below the current analyst price target, you have to ask: is Tango Therapeutics undervalued here, or is the market already pricing in future growth?

Preferred Price to Book Ratio of 7.6x: Is It Justified?

Tango Therapeutics currently trades on a P/B of 7.6x, which is well above both its US Biotechs peers and the wider industry, so the stock looks expensive on this yardstick.

P/B compares the market value of a company to its net assets on the balance sheet. It is often used for early stage or loss making biotechs where earnings are not yet a reliable guide. For Tango Therapeutics, this higher multiple sits alongside an unprofitable profile, with a reported loss of $107.232m and a negative return on equity, while shareholders have also been substantially diluted over the past year.

Against that backdrop, the 7.6x P/B stands out versus the US Biotechs industry average of 2.4x and a peer group average of 4.4x, suggesting investors are paying a clear premium compared to similar stocks. With no fair P/B ratio estimate or discounted cash flow value available, there is limited quantitative ballast to indicate where that premium could settle over time.

Result: Price-to-book ratio of 7.6x (OVERVALUED)

However, investors still face clear risks, including continued losses of US$107.232m and the fact that the stock already trades at a premium with a 7.6x P/B ratio.

Next Steps

Mixed signals like these can be hard to read, so move quickly, review the data for yourself, and carefully consider both risks and rewards using 1 key reward and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your goals even better, so take a few minutes to scan wider using focused screeners.

• Target potential mispricings by checking companies that combine quality fundamentals with attractive valuations through the 50 high quality undervalued stocks.
• Strengthen your income focus by reviewing stocks that offer robust yields and resilience via the 12 dividend fortresses.
• Prioritise resilience by zeroing in on companies that show lower overall risk using the 66 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.